KalVista Pharmaceuticals Says That Ten Abstracts Accepted For Presentation At The European Academy Of Allergy And Clinical Immunology Congress 2024
Portfolio Pulse from Benzinga Newsdesk
KalVista Pharmaceuticals announced that ten of its abstracts have been accepted for presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024, which will be held in Valencia, Spain from May 31 to June 3.
May 24, 2024 | 10:32 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
KalVista Pharmaceuticals will present ten abstracts at the EAACI Congress 2024, showcasing its research and developments in allergy and clinical immunology.
Presenting multiple abstracts at a major international congress can enhance KalVista's visibility and credibility in the field of allergy and clinical immunology, potentially attracting investor interest and positively impacting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100